Should Your Kids Know Their Genetic Cancer Risk? Your DNA Holds the Answer.

BRCA1 is one of your cells’ most important tumor suppression genes. Its job is to scan DNA for damage and fix it before that damage turns into cancer. Think of it as a security guard patrolling your cellular nuclei, identifying breaks in the DNA strand, and calling in repair crews to fix them before anything goes wrong.

When your child carries a pathogenic BRCA1 variant, that security guard is absent or severely weakened. The gene is still there, but it cannot do its job. Roughly 1 in 400 people in the general population carry a pathogenic BRCA1 variant. In people who carry it, lifetime breast cancer risk jumps to 55-72%, ovarian cancer risk to 39-46%, and pancreatic cancer risk to 1-2%. These are not small numbers. These are numbers that change medical management completely.

For your daughter, a BRCA1 variant means she will need MRI screening instead of mammography starting at age 25-30. It means she may choose preventive medication (tamoxifen) or even preventive surgery (risk-reducing mastectomy) before cancer ever develops. For your son, it means vigilance for male breast cancer and pancreatic cancer. The point is not to live in fear. The point is to know the risk and act accordingly.

BRCA2 works alongside BRCA1 as a DNA repair partner. While BRCA1 is the initial responder to DNA damage, BRCA2 helps relocalize the repair machinery and ensures the breaks are sealed correctly. It is essential for maintaining genomic stability in your cells.

A pathogenic BRCA2 variant impairs this repair process in exactly the same way a BRCA1 variant does. Roughly 1 in 800 people carry a pathogenic BRCA2 variant. People with BRCA2 variants face 45-69% lifetime breast cancer risk, 11-17% ovarian cancer risk, 5-7% pancreatic cancer risk, and elevated prostate cancer risk in men. Like BRCA1, BRCA2 is a game-changer. Your child’s life expectancy and cancer risk are fundamentally different depending on whether they carry this variant.

For your daughter, BRCA2 means the same intensive screening protocol and preventive medicine conversations as BRCA1. For your son, it means awareness that his cancer risk is elevated too, particularly for pancreatic cancer and prostate cancer. Many men don’t realize BRCA2 matters for them. It does.

MTHFR encodes methylenetetrahydrofolate reductase, an enzyme that converts dietary folate into its active form: methylfolate. This is a critical step in your cells’ methylation cycle, which powers DNA synthesis, detoxification, neurotransmitter production, and epigenetic gene regulation. Without active methylfolate, your entire cellular machinery runs in slow motion.

The MTHFR C677T variant reduces enzyme efficiency by 40-70%. Roughly 40% of people of European ancestry carry this variant. Children with the C677T variant cannot process folate as efficiently as their peers, leading to lower methylfolate levels and elevated homocysteine in the blood. Elevated homocysteine is an independent risk factor for cardiovascular disease, blood clots, and cognitive problems later in life. The variant also raises cancer risk slightly because DNA repair machinery depends on methylation.

For your child with MTHFR C677T, the intervention is straightforward: supplemental methylfolate instead of regular folic acid. This bypasses the broken conversion step and restores cellular methylation capacity. Many children with this variant struggle with fatigue, brain fog, and mood issues that resolve once methylation is optimized. This is not a rare condition. This is common enough that it changes how you think about your child’s nutrition.

Factor V (F5 gene product) is a crucial protein in your blood’s coagulation cascade. When you get a cut, Factor V helps activate the clotting pathway so your blood forms a stable plug and bleeding stops. This is a lifesaving function. But when the clotting cascade is too active, blood clots form inside blood vessels where they should not, causing deep vein thrombosis (leg clots), pulmonary embolism (lung clots), or stroke.

The Factor V Leiden variant (R506Q) makes Factor V resistant to inactivation by a natural anticoagulant called protein C. Roughly 5% of people of European ancestry carry one copy of this variant. Children who inherit Factor V Leiden have 4-8 times increased risk for venous thromboembolism compared to peers without the variant, and 80 times increased risk if they also take oral contraceptives (for daughters) or undergo prolonged immobilization. This is not a rare disease. This is a common inherited clotting disorder that can silently cause life-threatening blood clots.

For your child with Factor V Leiden, the risk is manageable but real. If your daughter takes oral contraceptives, her clot risk rises dramatically. If your child has surgery, they need thromboprophylaxis. Long flights and immobilization become risk factors they must actively manage. Knowing the variant transforms a potential emergency into a prevention plan.

HBB encodes beta-globin, a critical subunit of hemoglobin. Hemoglobin is the protein inside red blood cells that carries oxygen from your lungs to every cell in your body. Without functional beta-globin, your red blood cells cannot carry oxygen, and your cells suffocate.

Pathogenic HBB variants cause sickle cell disease (if a child inherits two copies) or sickle cell trait (if they inherit one copy). Sickle cell disease is one of the most serious inherited blood disorders, causing severe pain crises, organ damage, shortened lifespan, and multiple complications. Sickle cell trait is milder but still confers some disease risk and is important for family planning. In African ancestry populations, sickle cell disease affects roughly 1 in 365 children, and sickle cell trait affects 1 in 12. In other ancestry groups, the risk is lower but not zero. Carrier screening is now standard care in most developed countries because the interventions (hydration, pain management, preventive penicillin, gene therapy) are effective.

For your child with sickle cell disease, early diagnosis is lifesaving. Newborn screening has made an enormous difference. For your child who is a carrier (sickle cell trait), the main implications are genetic counseling for family planning and awareness that extreme physical exertion, dehydration, and high altitude can trigger complications. This is a gene where knowing the status transforms outcomes.

HLA-DQ2 is part of your immune system’s antigen presentation machinery. It sits on the surface of immune cells and displays protein fragments to T cells so they can decide whether those fragments are threats. In the gut, HLA-DQ2 displays peptides from food proteins, and your immune system decides whether to attack or tolerate them.

In people with the HLA-DQ2 variant, the immune system misidentifies gluten peptides as threats and launches an autoimmune attack against the intestinal lining. This is celiac disease. Roughly 30-40% of people carry HLA-DQ2, but only 2-3% develop celiac disease. Children who carry HLA-DQ2 and are exposed to gluten have a 2-3% lifetime risk of developing celiac disease, characterized by intestinal inflammation, nutrient malabsorption, and systemic autoimmune complications if untreated. The presence of HLA-DQ2 is necessary for celiac disease but not sufficient. Environmental exposure (gluten) and other genetic and epigenetic factors determine whether the disease manifests.

For your child with HLA-DQ2, the intervention depends on whether they have active celiac disease. If they do, the treatment is a strict gluten-free diet. If they don’t, periodic serological screening (tissue transglutaminase antibodies) makes sense, especially if they develop unexplained gastrointestinal symptoms, fatigue, or growth delay. Many children with undiagnosed celiac disease are labeled as picky eaters or anxious when the real problem is intestinal inflammation.